Publicacións nas que colabora con Berta Pernas Souto (25)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  2. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  3. Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

    Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  4. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies

    Journal of Medical Virology, Vol. 90, Núm. 6, pp. 1094-1098

2017

  1. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

    Journal of Medical Virology, Vol. 89, Núm. 7, pp. 1304-1308

  2. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

  3. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: Potential role as a biomarker of HIV replication

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 11, pp. 3159-3162

  4. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients

    Journal of Clinical Virology, Vol. 88, pp. 58-61

  5. Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: Impact for monitoring and optimizing treatment duration

    European Journal of Gastroenterology and Hepatology, Vol. 29, Núm. 7, pp. 781-785

  6. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1051-1055

  2. European mitochondrial haplogroups impact on liver fibrosis progression among HCV and HIV/HCV-coinfected patients from Northwest Spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 73, Núm. 2, pp. 149-153

  3. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain

    Journal of Medical Virology, Vol. 88, Núm. 12, pp. 2125-2131